Brief: ExpreS2ion Biotech Holding AB Says Positive Topline Results Reported For Phase II Covid-19 Clinical Trial With ABNCoV2 Vaccine

ExpreS2ion Biotech Holding AB

05/12/2021 18:51

Dec 5 (Reuters) - ExpreS2ion Biotech Holding AB  EXPRS2.ST :
    * POSITIVE TOPLINE RESULTS REPORTED FOR PHASE II COVID-19
CLINICAL
TRIAL WITH ABNCOV2 VACCINE
    * ABNCOV2 VACCINE DEMONSTRATED A STRONG BOOSTING EFFECT IN
CLINICAL PHASE II TRIAL CONDUCTED BY BAVARIAN NORDIC
    * EXPRES2ION BIOTECH HOLDING - EXISTING LEVELS OF SARS-COV-2
NEUTRALIZING ANTIBODIES INCREASED BY 2-40-FOLD, WITH NO SERIOUS
ADVERSE EVENTS REPORTED
    * TOPLINE RESULTS CONFIRM VACCINE'S EXCELLENT PROFILE AS A
NON-ADJUVANTED UNIVERSAL COVID-19 BOOSTER VACCINE
    * ALL SUBJECTS WERE BOOSTED TO ABSOLUTE ANTIBODY LEVELS
REPORTED
TO BE ASSOCIATED WITH HIGH EFFICACY (>90%) AGAINST SARS-COV2
    * EXPRES2ION BIOTECH HOLDING - BAVARIAN NORDIC IS ALSO
PREPARING
FOR A PHASE III TRIAL OF ABNCOV2, EXPECTED TO BE INITIATED IN
FIRST HALF OF 2022

Source text for Eikon:  ID:nWkr8yKN9n 
Further company coverage:  EXPRS2.ST 

 ((reuters.briefs@thomsonreuters.com;))